Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Ageing Research Reviews February 1, 2024 Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh et al. 29 citations
Psychedelics such as DMT, LSD, and psilocybin, which act as potent 5-hydroxytryptamine agonists, enhance neural plasticity by activating serotoninergic and glutamatergic systems and modulate signaling pathways in Alzheimer's disease, including brain-derived neurotrophic factor signaling and subsequent activation of mammalian target of rapamycin and autophagy regulators. These compounds show potential for mitigating effects of Alzheimer's disease-related dementia, which lacks a definitive cure. Controlled, dose-dependent administration represents a novel therapeutic intervention, though further studies are needed to establish long-term safety, efficacy, and optimal protocols.